Cancer

Prostate Cancer Foundation

OncoLink was founded in 1994 by Penn cancer specialists with a mission to help cancer patients, families, health care professionals and the general public get accurate cancer-related information at no charge. Recent changes have been made to OncoLink to update the look and feel of our site. OncoLink is designed to make it easy for the general public to navigate through the pages to obtain the information that they want. The home page has buttons and hypertext links. If you click on the buttons or the underlined text with your mouse, you will go directly to your area of interest.

Whether you're deciding on brachytherapy or are interested in nutraceuticals and diet, Prostate Forum tackles the latest on prostate cancer and beyond, responding with timely information for men of any age or at any stage of treatment.\n\nDr. Myers answer

The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is the third most common cause of death from cancer in men of all ages. It is rare in men younger than 40. Levels of a substance called prostate specific antigen (PSA) is often high in men with prostate cancer. However, PSA can also be high with other prostate conditions. Since the PSA test became common, most prostate cancers are found before they cause symptoms. Symptoms of prostate cancer may include Problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling Low back pain Pain with ejaculation Prostate cancer treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Treatment may include surgery, radiation therapy, chemotherapy or control of hormones that affect the cancer.

American Society of Clinical Oncology Meeting 2006.

The American Society of Clinical Oncology (ASCO) is a non-profit organization, founded in 1964, with overarching goals of improving cancer care and prevention and ensuring that all patients with cancer receive care of the highest quality. More than 25,000 oncology practitioners belong to ASCO, representing all oncology disciplines (medical, radiation, and surgical oncology) and subspecialties. Members include physicians and health-care professionals participating in approved oncology training programs, oncology nurses, and other practitioners with a predominant interest in oncology.

Sharing experiences, support and advise for men with advanced & recurrent Prostate Cancer

The National Cancer Institute's research programs are extensive and contain many innovative initiatives. I invite you to explore our Web site to find out more about the exciting work being conducted here at NCI and by NCI-supported scientists throughout the country. You will also find valuable cancer-related information of all kinds. For the general public, patients, and health professionals, we offer consumer-oriented information on a wide range of topics as well as comprehensive descriptions of our research programs and clinical trials. Scientists will find detailed information on specific areas of research interest and funding opportunities.

This web site is dedicated to vitamin D and cancer. This is because exciting new research indicates that vitamin D-whether produced in the skin as a result of exposure to ultraviolet radiation (from sunlight or sun lamps) or obtained from supplementation with cholecalciferol (vitamin D3)-may help cancer patients. However, the research is far from complete.

ScienceDaily (Feb. 22, 2009) - Cancer cells need a lot of nutrients to multiply and survive. While much is understood about how cancer cells use blood sugar to make energy, not much is known about how they get other nutrients. Now, researchers at the Johns Hopkins University School of Medicine have discovered how the Myc cancer-promoting gene uses microRNAs to control the use of glutamine, a major energy source. The results, which shed light on a new angle of cancer that might help scientists figure out a way to stop the disease, appear Feb. 15 online at Nature

Ginkgo biloba extract EGb(R)761 exerts anti-angiogenic effects via activation of tyrosine phosphatases. Koltermann A, Liebl J, Fürst R, Ammer H, Vollmar AM, Zahler S. J Cell Mol Med. 2008 Oct 23. [Epub ahead of print] PMID: 19175691

anti

Country Profiles